SOMMARIO

P. Giomarelli: Il monitoraggio nel paziente critico; il \( \text{VCO}_2 \) come parametro guida ................................................. 5

P. Mamone; A. Pucci; R. Fioretto; C. Comizio; R. Libutti; M. Di Segni; G. Bertoluzza; G. Angelica; A. Chiantera; G. Attanasio; L. C. d'Alessandro: Gli aneurismi dell'aorta toracica. Risultati operatori e follow-up a distanza su 259 casi trattati chirurgicamente ........................................... 10

R. Fioretto; P. Mamone; C. U. Cacchiani: Attuali metodiche ricostruttive con lembo miocutanee nel trattamento delle osteoradionecrosi e dell'interessamento della parete toracica da carcinoma della mammella ........................................... 20

M. Iaenziandri; S. Chieregi; L. Romanello; S. Cerbone; F. De Nellili; C. Monaco; C. Gentile: Influencia dell'uso della aprotinin sulle perdite di sangue in pazienti cardiochirurgici ................................................................. 23

Q. Tecz; A. Berrafato; T. Cioania; G. Colorese; C. Cifone; R. Nardo; F. Colace: Monitoraggio della \( \text{SaO}_2 \) in arteria polmonare con catetere di Swan-Ganz a fibre ottiche. Introduzione teorica e sua utilità in cardiologia ................................................................. 31

R. Fioretto; M. G. Splendore; P. Mamone; C. U. Cacchiani; R. I. S. (Radio Immunoguided Surgery): nuovo intervento chirurgico in tumori ed uteri cancer ..................................................... 40

P. Mamone: L'informatica in cardiologia e cardiochirurgia: presente e futuro ................................................................. 43

G. Sant; G. Libi; M. Maccherini; L. Marchetti; P. Gionarelli; B. Mezzacapo; M. Torsiani; Trattamento chirurgico dell'infarto miocardico acuto in fase evolutiva. Nostra esperienza ........................................................................ 46

STATUTO DELL' A. I. R. S. M. C. ................................................................. 54
R. FIORITO; M. G. SPLENDORI*; P. MAMONE**; C. U. CASCIANI

R.I.G.S. (RADIO IMMUNO GUIDED SURGERY): NEW SURGICAL TREATMENT IN THE EARLY AND HIDDEN BREAST CANCER

The rising incidence of the breast cancer and its high death rate, request a diagnostic program and a disease check as precise as possible.

Up to now remarkable advantages has raised from the intensification of common efforts in the field of early diagnosis and the method, which aim to determine the correct stadiation of the cancer before surgical procedure, are now standard (mammography, F.N.A.B., and ecographic check). We do hope, despite the high precision of those diagnostic techniques, the bringing out metastasis of an hidden cancer (x rays deaf) does not occur even if not very often for one 0.5 to 7% of the patients.

Particularly the most up diaphragmatic place concerned, is the lung, while for the down diaphragmatic is pancreas.

The axillary region are concerned by the hidden cancer in 63-65% of the cases, while the skeleton is concerned for the 33% of cases, showing, as underlined by Nyström, that often the metastatic diffusion of the hidden cancer does not follow the same patterns as the cancers clinically evident.

In those conditions it is necessary to try to define with accuracy the location and the extension of the primitive cancer on the one hand to avoid complications (quick metastasis) on the other to carry out an immediate and radical therapy in order to obtain an augmentation of the time of survival.

For this purpose, those farse years, in many hospitals, researchers are testing the efficacy of monoclonal antibodies (Mabs) that, armed with radionucleated particles or with chemotherapeutic agents, binding with specific tumoral glicoproteins could manage to concentrate them selves in the sub-clinic neoplastic focus.

Because of this affinity, it becomes possible to diagnose precociously the primary places of the tumor, the metastasis that does not come out with normal methods and kill with a direct method or with a "chain reaction" only the neoplastic cells.

Together with the Mabs (anti MCA, anti Ca 15-3, and Mab ER-D5) direct against the antigens associated with the cancer of the breast with a specificity of 85%, there is the recent discovery of a Mab of rat origin called B.72.3.

This Mab, utilized as a reliever could be used successfully for the development of a new surgical approach: the radioimmuno guided one, that could give a real stadiation either pre surgical or intra surgical, and could allow us to obtain exact informations about the extension of the neoplastic focus and to efficaciate a most radical surgical exciresis.

In fact, this Mab armed with radionucleid-I-125, could have an high affinity with the surface tumoral antigen TAG 72 present in the cellular membrane of many human neveecriting epithelia.

In a particular way the affinity could be with the membranes of adenocarcinomas of the breast (85-90% of specificity), of the colon (80-85%), of the lung (85%), of the ovary and pancreas (75-85%).

The specific link with neoplastic cells, globally displayed with radiodiagnostic techniques after two weeks from the intravenous administration of Mab-I-125, could be relieved during the surgical intervention thanks to a detector probe (Neoprobe system 1000) that would translate into an acoustic signal the gamma radiations coming from the accumulation of the complex Mab-I-125 in the concerned neoplastic tissue only.

This would allow us to know the exact extension of the neoplastic focus, permitting us to perform with a high degree of security a preservative surgical intervention or to enlarge the margins of the resection in case of need.

This specific system of revelation could be the fondamental base for the development of this new surgical technique (R.I.G.S.) that could be more reliable for the high capacity of the definition of the extension of the cancer and for the possibility to identify clinically those metastasis that area radiologically hidden. Alone, or associated with other techniques (radio - immuno - chemo - thermo - therapies), personalized on the istohistochemical features of any single tumor, could become the elected method in the execution of a true radical treatment, with an important resection of local relapse and metastatic repetitions.

The employment of this technique is strongly limited on the one hand because of the impossibility to create human Mabs in laboratories and on the other hand because the production of Mabs is very expensive.

We do hope in a stronger cooperation between highly specialized centers for the identification, with more and more selective methodologies, either of new prognostic factors concerning the breast carcinoma or in more radical strategies in order to kill this social disease.

References

2) Colcher D., Zalatsky M., Kaplan W.:


